课题基金 / 基金详情

Etiology, pathopysiology and treatment of NK cell-lineage leukemias and lymphomas

Etiology, pathopysiology and treatment of NK cell-lineage leukemias and lymphomas
NK 细胞系白血病和淋巴瘤的病因学、病理生理学和治疗
批准号:
07457234
负责人:
OSHIMI Kazuo
金额:
$4.86万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
1995
资助国家:
日本
项目状态:
已结题
起止时间:
1995 至 1996

项目摘要

项目成果

OSHIMI Kazuo的其他基金

相似基金

相关文献

中文摘要
翻译
1. eb病毒(EBV)在NK细胞中的感染。从NK细胞疾病病例的研究来看,EBV被认为是侵袭型NK- glpd和NK细胞淋巴瘤的病因。然而,在惰性型NK-GLPD中,EBV似乎与该疾病无关。NK细胞在不同类型NK细胞疾病中的表征。从不同类型NK细胞疾病患者获得的NK细胞,从表面表型、细胞谱系、发育阶段、细胞毒性、t细胞受体(TCR)和IgH基因等方面进行研究。在鼻腔NK细胞淋巴瘤中,恶性NK细胞似乎是被激活的成熟NK细胞,而不是未成熟NK细胞。在NK- glpd中,不确定侵袭型NK- glpd的NK细胞是未成熟细胞还是活化的成熟NK细胞,而发现惰性型NK- glpd的NK细胞是活化的成熟NK细胞。对正常NK细胞、鼻NK淋巴瘤细胞、侵袭型NK- glpd细胞、惰性型NK- glpd细胞和两种NK细胞系的NK细胞进行P-gp表达检测。除1株NK细胞外,其余NK细胞均表达P-gp。此外,环孢素A及其衍生物PSC833的加入抑制了P-gp的功能。由于这些药物对P-gp功能的体外研究,它们的体内功能必须明确。用EBV对NK细胞的体外转化进行了试验。初步研究表明EBV可能感染正常NK细胞和NK细胞系。现在这一发现正被其他技术所证实。
英文摘要
1. Infection of Epstein-Barr virus (EBV) in NK cells.From the studies of cases of NK cell disorders, EBV was considered to be the etiologic agentin aggressive-type NK-GLPD and NK-cell lymphomas. In indolent-type NK-GLPD,however, EBV seemed to be unrelated to the disorder.2. Characterization of NK cells in various types of NK-cell disorders.NK cells obtained from patients with various types of NK-cell disorders were studied in terms of surface phenotype, cell lineage, developmental stage, cytotoxicity, and T-cell receptor (TCR) and IgH genes. In nasal NK-cell lymphoma, malignant NK cells seemed to be activated mature NK cells, but not to be immature NK cells. In NK-GLPD,it is uncertain whether NK cells of aggressive-type NK-GLPD are immature cell sor activated mature NK cells, and NK cells of indolent-type NK-GLPD were found to be activated mature NK cells.3. Expression of multidrug resistance (MDR) 1-coded P-glycoprotein (P-gp) on NK cellsNK cells including normal NK cells, nasal NK lymphoma cells, aggressive type NK-GLPD cells, indolent-type NK-GLPD cells, and two NK-cell lines were tested fortheir expression of P-gp. Except one NK-cell line, all the NK cells tested were found to express P-gp. Further, the function of P-gp was inhibited by the addition of cyclosporin A and its derivative PSC833. Because of these in vitro study of these drugs on P-gp function, their in vivo function must be delineated.4. Transformation of NK cells with EBVIn vitro transformation of NK cells with EBV has been tried. A preliminary study indicates the possible infection of EBV into normal NK cells and a NK cell line. Now the finding is being confirmed by other techniques.
期刊论文(14)
专著(0)
科研奖励(0)
会议论文
Kaneko T et al.: "Nasal natural Killer(NK) cell lymphoma : report of a case with activated NK cells contairing Epsteim-Barr virus and・・・" British Jounal of Haematology. 91. 355-361 (1995)
Kaneko T 等人:“鼻自然杀伤 (NK) 细胞淋巴瘤:含有 Epsteim-Barr 病毒的活化 NK 细胞病例报告和……”英国血液学杂志 91. 355-361 (1995)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Semenzato G et al.: "The lymphoprobiferative disease of……" Blood. 63. 256-260 (1997)
Semenzato G 等人:“……的淋巴组织增生性疾病”,《血液》63. 256-260 (1997)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Semenzato G,Zambello R,Starkebaum G,Oshimi K,Loughran TP: "The lymphoprolif erative disorders of granular lymphocytes : updated criteria for diagnosis." Blood. 89. 256-260 (1997)
Semenzato G,Zambello R,Starkebaum G,Oshimi K,Loughran TP:“颗粒淋巴细胞的淋巴增殖性疾病:更新的诊断标准。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
共 13 条
    Induction of specific cytotoxicity for autologous leukemic cells by the use of keller T cells and bispecific antibodies
    • 批准号:
      02454522
    • 项目类别:
      Grant-in-Aid for General Scientific Research (B)
    • 资助金额:
      $2.3万
    • 财政年份:
      1990
    • 负责人:
      OSHIMI Kazuo
    • 依托单位:
    Morphology and function of lymphocytes expanded in granular lymphocyte leukemia
    • 批准号:
      63480280
    • 项目类别:
      Grant-in-Aid for General Scientific Research (B)
    • 资助金额:
      $3.52万
    • 财政年份:
      1988
    • 负责人:
      OSHIMI Kazuo
    • 依托单位:
    IL-2-activated lymphocytes lytic for autologous leukemia and lymphoma cells: some problems on their clinical application.
    海外基金